Comparison · NCT01876082-sae
PAZOPANIB vs Vinblastine and Methotrexate: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. PAZOPANIB vs Vinblastine and Methotrexate: serious adverse events. Trial comparisons, record NCT01876082-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01876082-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.417 | 0.288 | 0.557 | wilson | |
| Risk in group 2 | 0.455 | 0.269 | 0.653 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0379 | -0.274 | 0.195 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.917 | 0.52 | 1.62 | log | |
| Odds ratio, group 1 over group 2 | 0.857 | 0.31 | 2.37 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on PAZOPANIB than on Vinblastine and Methotrexate | 26.4 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | PAZOPANIB | Pazopanib~* 800 mg per day~* oral administration~* at least 1 hour before or 2 hours after a meal,~* until disease progression or for 12 months maximum~PAZOPANIB treatment: Pazopanib~* 800 mg per day~* oral administration~* at least 1 hour before or 2 hours after a meal,~* until disease progression or for 12 months maximum | 20 | 48 | EG000 |
| Group 2 | Vinblastine and Methotrexate | vinblastine 5 mg / m², methotrexate 30 mg / m (J1, J8, J15, J21, 6 months and then J1, J15) 28 days per cycle until disease progression or for 12 months.~Active Comparator: Vinblastine and Methotrexate: Active Comparator: Vinblastine and Methotrexate vinblastine 5 mg / m², methotrexate 30 mg / m (J1, J8, J15, J21, 6 months and then J1, J15) 28 days per cycle until disease progression or for 12 months. | 10 | 22 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- 2 years
Source ClinicalTrials.gov
Trial
- Title
- PAZOPANIB Efficacy and Tolerance in Desmoids Tumors
- NCT number
- NCT01876082
- Phases
- PHASE2
- Conditions
- Progressive Desmoids Tumors
- Interventions
- PAZOPANIB treatment, Active Comparator: Vinblastine and Methotrexate
- Lead sponsor
- Institut Bergonié
- Results first posted
- 2021-03-05
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01876082?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01876082-sae